查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2017001

治療性疫苗市場：2026-2032年全球市場預測（依適應症、技術平台、給藥途徑、最終用戶及通路分類）

Therapeutic Vaccines Market by Indication, Technology Platform, Administration Route, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，治療性疫苗市場價值將達到 366 億美元，到 2026 年將成長至 405.4 億美元，到 2032 年將達到 746.5 億美元，複合年成長率為 10.71%。

主要市場統計數據
基準年 2025 366億美元
預計年份：2026年 405.4億美元
預測年份 2032 746.5億美元
複合年成長率 (%) 10.71%

透過整合科學進步、監管變化和相關人員的期望，為治療性疫苗領域的決策者提供策略框架。

治療性疫苗領域正處於一個轉折點，這得益於科學進步和商業性趨勢的轉變。抗原發現、免疫調節和遞送技術的最新進展，已使治療性疫苗從小眾的科學研究領域轉變為涵蓋腫瘤、感染疾病、自體免疫免疫疾病和神經系統疾病等多種適應症的策略性治療方法。本導言概述了核心科學證據、法規環境以及相關人員的期望，這些因素共同塑造了研發者、生產者和支付方的短期策略重點。

重大的技術、監管和製造變革正在共同作用，重新定義治療性疫苗的研發路徑和商業策略。

治療性疫苗領域正經歷一系列變革性變化，這些變化正在改變產品的研發、生產、監管和商業化方式。 mRNA和自擴增RNA平台的快速發展，以及脂質奈米顆粒遞送技術和抗原篩選方法的改進，正在縮短從藥物發現到第一線人體試驗的時間。同時，病毒載體工程、全細胞和樹突狀細胞策略正在將治療範圍擴展到以前無法治療的適應症，尤其是在腫瘤學和複雜感染疾病領域。這些平台技術的進步使得更精準的免疫編程成為可能，並促進了聯合療法的發展，透過將疫苗與免疫查核點抑制劑和標靶治療相結合，從而提高療效。

2025 年美國關稅政策的變化將如何影響治療性疫苗研發公司的供應鏈策略、生產在地化和採購慣例？

美國2025年實施的關稅政策調整的累積影響，為治療性疫苗的採購、生產和決策等各環節的相關人員帶來了新的考量。某些生物製藥原料和組件的進口關稅上調，導致奈米顆粒載體所需的脂質、質體DNA生產所需的原料以及病毒載體生產中使用的特殊試劑等關鍵原料成本上升。因此，供應鏈規劃現在更加重視供應商多元化和策略性庫存管理，以降低價格波動和運輸延誤的風險。

將適應症的生物學特徵、平台選擇、給藥途徑、分銷管道和最終用戶情況與策略項目設計聯繫起來的詳細細分見解。

針對特定領域的趨勢正在推動整個治療性疫苗計畫在臨床、監管和商業策略上的差異化，適應症、平台、給藥途徑、分銷管道和最終用戶因素等因素都會影響研發方案的選擇。根據適應症的不同，研發重點也有顯著差異。在自體免疫疾病（例如紅斑性狼瘡、多發性硬化症、類風濕性關節炎和第1型糖尿病）中，抗原特異性耐受性和免疫調節是研發重點。在癌症計畫中，研發重點是乳癌、子宮頸癌、大腸癌、黑色素瘤和攝護腺癌等腫瘤類型，在這些疾病中，新抗原標標靶化和聯合治療至關重要。在感染疾病中，研發重點是巨細胞病毒(CMV)、肝炎病毒、HIV、HPV 和流感病毒等病原體，根除免疫和持續控制是關鍵目標。在阿茲海默症、肌萎縮側索硬化症 (ALS)、癲癇和帕金森氏症等神經系統疾病中，血腦障壁的傳遞和神經發炎的調節是重大的科學挑戰。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢影響著監管策略、製造決策和市場進入計畫。

區域趨勢對研發重點、監管策略和商業化路徑有著深遠的影響，因此，在美洲、歐洲、中東、非洲和亞太市場，制定具有區域意識的規劃至關重要。在美洲，健全的創新生態系統、強大的創投和企業投資以及完善的法規結構，促進了快速的臨床開發和官民合作關係。同時，多樣化的支付方體係要求研發人員制定靈活的循證方案，以適應不同的報銷模式。該地區還擁有大規模的生產能力和緊密的合約研發生產機構（CDMO）網路，這有利於實現生產在地化並降低供應鏈風險。

主要企業的企業策略和夥伴關係如何協調平台專業知識、製造擴充性和以支付方為中心的證據產生？

治療性疫苗生態系統中主要企業的競爭行為和企業策略體現了平台多元化、針對特定適應症的產品組合以及連接研發、生產和商業化能力的策略夥伴關係。主要企業正致力於平台整合，以充分利用其核心研發投資，涵蓋多種適應症；而其他企業則專注於樹突狀細胞療法和病毒載體工程等細分治療方法，以實現科學差異化。生物技術公司、學術機構和契約製造（CMO）之間的跨領域合作日益普遍，旨在加速轉化研究並確保臨床和商業規模的供應鏈能力。

為開發商和製造商提供可操作且優先的行動方案，以確保供應彈性，簡化與監管機構的合作，並向支付方和患者展示長期價值。

產業領導者應制定一套切實可行的優先事項，以平衡科學目標、營運韌性和以支付方為導向的證據產生。首先，應實現關鍵原料供應商網路的多元化，並優先認證替代生產商，以降低貿易相關風險和單一來源風險。投資區域製造能力和策略夥伴關係，既能減少跨境政策變化的影響，又能縮短臨床和商業供應的前置作業時間。

採用透明且多方面的研究途徑，整合文獻、專家訪談、管道分析和供應鏈診斷，以獲得可靠的見解。

本分析的調查方法採用了一種嚴謹的多維度方法，以確保其相關性、可靠性以及對策略決策者的價值。該過程首先對同行評審文獻、監管指導文件、臨床試驗註冊資訊、專利申請和行業白皮書進行了全面審查，以建立對科學進展和監管先例的基本理解。基於這些二手研究的結果，我們進行了一項有針對性的一手調查，包括對臨床研究人員、生產專家、監管顧問、支付方代表和供應鏈專家進行結構化訪談，以了解從業人員的觀點和營運限制。

一份權威的綜合分析報告強調，需要將科學創新與製造業的韌性、與支付方的合作以及分階段的專案規劃結合，才能產生實際影響。

總之，治療性疫苗有望在癌症、感染疾病、自體免疫疾病和某些神經系統疾病中實現持續的疾病管理，並在精準醫療的未來發展中發揮關鍵作用。核酸平台、病毒載體和細胞療法的科學進步，以及不斷發展的監管途徑和生產製造創新，為有意義的臨床進展創造了沃土。然而，要充分發揮這一潛力，需要積極主動地管理供應鏈的韌性，儘早與支付方和監管機構開展合作，並根據不同的給藥途徑和終端用戶環境，謹慎調整生產和分銷策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 治療性疫苗市場：依適應症分類

  • 自體免疫疾病
    • 狼瘡
    • 多發性硬化症
    • 類風濕性關節炎
    • 1型糖尿病
  • 癌症
    • 乳癌
    • 子宮頸癌
    • 結腸癌
    • 惡性黑色素瘤
    • 攝護腺癌
  • 感染疾病
    • CMV
    • 肝炎
    • HIV
    • HPV
    • 流感
  • 神經系統疾病
    • 阿茲海默症
    • 肌萎縮側索硬化症（ALS）
    • 癲癇
    • 帕金森氏症

第9章 按技術平台分類的治療性疫苗市場

  • 樹突狀細胞
  • 胜肽
  • RNA
    • mRNA
    • 自擴增RNA
  • 病毒載體
    • 腺病毒
    • 慢病毒
    • 牛痘病毒
  • 全細胞

第10章：依給藥途徑分類的治療性疫苗市場

  • 皮內注射
  • 肌肉內部
  • 靜脈
  • 皮下

第11章 治療性疫苗市場：依最終用戶分類

  • 診所
  • 醫院
  • 研究機構

第12章 治療性疫苗市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 治療性疫苗市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 治療性疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 治療性疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國治療性疫苗市場

第17章：中國治療性疫苗市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agenus Inc.
  • AstraZeneca
  • BioNTech SE（active in personalized cancer vaccines）
  • Celldex Therapeutics
  • CSL Limited
  • CureVac
  • Dendreon Pharmaceuticals LLC
  • GSK plc
  • Immatics Biotechnologies
  • Inovio Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Moderna
  • Novartis AG
  • Pfizer, Inc.
Product Code: MRR-030298DFF753

The Therapeutic Vaccines Market was valued at USD 36.60 billion in 2025 and is projected to grow to USD 40.54 billion in 2026, with a CAGR of 10.71%, reaching USD 74.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 36.60 billion
Estimated Year [2026] USD 40.54 billion
Forecast Year [2032] USD 74.65 billion
CAGR (%) 10.71%

A strategic framing that synthesizes scientific progress, regulatory shifts, and stakeholder expectations to orient decision-makers in the therapeutic vaccines sector

The therapeutic vaccines landscape is at an inflection point driven by converging scientific advances and evolving commercial dynamics. Recent progress in antigen discovery, immune modulation, and delivery technologies has transformed therapeutic vaccines from a niche scientific pursuit into a strategic modality across oncology, infectious disease, autoimmune disorders, and neurological indications. This introduction frames the core scientific rationale, regulatory environment, and stakeholder expectations that collectively shape near-term strategic priorities for developers, manufacturers, and payers.

Clinicians and executives are navigating a complex environment in which precision immunologic targeting is maturing alongside sophisticated platform technologies such as nucleic acid-based constructs, viral vectors, and cell-based formulations. Meanwhile, regulatory authorities are refining evidentiary pathways for efficacy endpoints, real-world evidence integration, and adaptive approval mechanisms, which influences product development timelines and launch strategies. Taken together, these dynamics create both opportunity and responsibility: to design trials that demonstrate durable clinical benefit, to invest in scalable manufacturing, and to construct pricing and access models that reflect long-term value for patients and health systems.

Consequently, understanding therapeutic vaccines requires a multidimensional lens that spans indication-specific biology, platform capabilities, administration and distribution realities, and the stakeholder economics that determine adoption. This executive summary establishes that lens and prepares the reader for deeper analysis of transformative industry shifts, policy influences, segmentation implications, regional dynamics, competitive behavior, and actionable recommendations.

Major technological, regulatory, and manufacturing shifts are converging to redefine development pathways and commercial strategies for therapeutic vaccines

The therapeutic vaccines arena is being reshaped by a series of transformative shifts that alter how products are developed, manufactured, regulated, and commercialized. Technological acceleration in mRNA and self-amplifying RNA platforms, coupled with improved lipid nanoparticle delivery and refined antigen selection methods, is compressing timelines from discovery to first-in-human studies. At the same time, viral vector engineering and whole cell or dendritic cell strategies are expanding therapeutic reach into indications previously deemed intractable, particularly within oncology and complex infectious diseases. These platform advances are enabling more precise immune programming and combination strategies that pair vaccines with checkpoint inhibitors or targeted therapies to enhance efficacy.

Regulatory frameworks are adapting in parallel to accommodate adaptive trial designs, surrogate endpoints, and expedited pathways focused on meaningful clinical outcomes. Payers and health systems are increasingly demanding robust value demonstration, encompassing durability of response and downstream cost offsets, which is steering developers toward integrated health economics and outcomes research early in development. Additionally, manufacturing innovation-such as modular facilities, single-use bioprocessing, and decentralized production models-is reducing technical barriers to scale while raising expectations for supply chain resilience and quality assurance.

Taken together, these shifts are driving a new industry architecture in which cross-disciplinary collaboration, flexible regulatory engagement, and strategic manufacturing investments determine competitive differentiation. Organizations that align scientific ambition with pragmatic commercialization planning and stakeholder engagement will be best positioned to translate immunologic advances into meaningful patient impact and sustainable commercial outcomes.

How shifts in US tariff policy enacted in 2025 are influencing supply chain strategies, manufacturing localization, and procurement practices across therapeutic vaccine developers

The cumulative effect of tariff policy changes implemented in the United States in 2025 has introduced a new set of considerations for therapeutic vaccine stakeholders that extend across sourcing, manufacturing, and procurement decisions. Increased import tariffs on certain biologics inputs and components have elevated the cost of critical raw materials such as lipids for nanoparticle carriers, plasmid DNA production inputs, and specialty reagents used in viral vector manufacturing. As a result, supply chain planning has moved toward greater emphasis on supplier diversification and strategic inventory management to mitigate price volatility and potential shipment disruptions.

In response to tariff-driven cost pressures, some developers have accelerated initiatives to localize manufacturing operations and qualify domestic contract development and manufacturing organizations to reduce exposure to cross-border duties. This shift has implications for capital allocation and lead-time management, as building or repurposing facilities requires significant operational planning. Moreover, procurement teams are re-evaluating sourcing strategies and total landed cost analyses to incorporate tariff implications alongside transportation, cold chain logistics, and regulatory compliance overhead.

Regulatory and commercial stakeholders are also adapting to these trade policy effects. Payers and contracting entities are scrutinizing cost inputs more closely, which reinforces the need for early health economic modeling and transparent supply cost narratives. Policy uncertainty has increased interest in multi-sourcing, strategic stockpiles for critical inputs, and collaborative risk-sharing agreements between developers and manufacturing partners. Ultimately, the 2025 tariff landscape underscores the importance of resilient supply chains, proactive procurement strategies, and policy-aware commercial planning to preserve program timelines and patient access.

Deep segmentation insights that connect indication biology, platform selection, administration routes, distribution channels, and end-user realities to strategic program design

Segment-specific dynamics drive differentiated clinical, regulatory, and commercial strategies across therapeutic vaccine programs, with indication, platform, administration route, distribution channel, and end-user considerations each shaping development choices. Based on indication, development focus varies widely: autoimmune diseases target conditions such as lupus, multiple sclerosis, rheumatoid arthritis, and type 1 diabetes where antigen-specific tolerance and immune modulation are priorities; cancer programs concentrate on tumor types including breast, cervical, colorectal, melanoma, and prostate cancer where neoantigen targeting and combination regimens are critical; infectious disease efforts prioritize pathogens such as CMV, hepatitis viruses, HIV, HPV, and influenza where sterilizing immunity or durable control are the central endpoints; and neurological disorder initiatives address Alzheimer's disease, amyotrophic lateral sclerosis, epilepsy, and Parkinson's disease where blood-brain barrier delivery and neuroinflammation modulation are key scientific hurdles.

Based on technology platform, the choice between dendritic cell approaches, DNA platforms (including plasmid constructs), peptide vaccines, RNA platforms (comprising mRNA and self-amplifying RNA), viral vectors (including adenovirus, lentivirus, and vaccinia virus), and whole cell formulations materially alters manufacturing, regulatory engagement, and clinical trial design. RNA platforms typically demand advanced cold chain and delivery technologies, DNA plasmid workflows emphasize high-quality plasmid production and transfection strategies, and viral vector modalities require containment, potency assays, and specialized viral vector analytics. Dendritic cell and whole cell approaches often necessitate individualized or semi-personalized manufacturing workflows and close coordination with clinical sites.

Based on administration route, intradermal, intramuscular, intravenous, and subcutaneous delivery choices influence patient experience, dosing schedules, and the logistical footprint required for outpatient or inpatient administration. Based on distribution channel, hospital pharmacies, online pharmacies, and retail pharmacies present distinct fulfillment, storage, and reimbursement considerations that affect launch planning and patient access pathways. Based on end user, clinics, hospitals, and research institutes differ in procurement processes, clinical capabilities, and infrastructure readiness for specialized administration or investigational product handling. Integrating these segmentation layers into program planning enables sponsors to tailor clinical protocols, manufacturing scale, commercial access strategies, and stakeholder engagement plans to the realities of each therapeutic context.

Region-specific dynamics across the Americas, Europe Middle East and Africa, and Asia-Pacific that shape regulatory strategy, manufacturing decisions, and market access planning

Regional dynamics exert powerful influence over development priorities, regulatory strategy, and commercialization pathways, necessitating region-aware planning across the Americas, Europe Middle East and Africa, and Asia-Pacific markets. In the Americas, strong innovation ecosystems, robust venture and corporate investment, and established regulatory frameworks encourage rapid clinical development and public-private partnerships, while payer systems vary, prompting developers to design flexible evidence-generation plans that support diverse reimbursement models. The region also hosts significant manufacturing capacity and a dense network of contract development and manufacturing organizations, which supports efforts to localize production and reduce supply chain exposure.

The Europe, Middle East and Africa region presents a complex mosaic of regulatory agencies, health technology assessment processes, and access landscapes. In many European markets, stringent value demonstration and centralized or coordinated procurement mechanisms require early alignment with health technology assessment bodies and multi-country clinical strategies. Regulatory convergence initiatives alongside regional centers of excellence for clinical trials and manufacturing present opportunities for strategic partnerships, but developers must navigate diverse reimbursement timelines and pricing pressures.

The Asia-Pacific region combines rapid clinical trial enrollment capacity, emerging manufacturing scale, and variable regulatory maturity. Several jurisdictions are accelerating regulatory reforms to facilitate innovative therapies, while others maintain more conservative pathways that demand localized data. Cost-conscious payers and rapidly growing healthcare infrastructure in certain markets create both challenges and opportunities for differentiated market-entry strategies. For all regions, cross-border collaborations, regional manufacturing hubs, and adaptive regulatory engagement strategies can optimize clinical timelines, improve supply reliability, and enhance patient access outcomes.

How corporate strategies and partnerships among leading companies are aligning platform specialization with manufacturing scalability and payer-focused evidence generation

Competitive behavior and corporate strategy among key companies in the therapeutic vaccines ecosystem reflect diversification across platforms, targeted indication portfolios, and strategic partnerships that bridge research, manufacturing, and commercialization capabilities. Leading organizations are pursuing platform consolidation to leverage core R&D investments across multiple indications, while others specialize in niche modalities such as dendritic cell therapies or viral vector engineering to capture scientific differentiation. Cross-sector alliances between biotechnology companies, academic centers, and contract manufacturers are increasingly common, aimed at accelerating translational work and ensuring supply chain capacity for clinical and commercial scale.

Partnership models vary from early-stage collaborations that co-develop antigen constructs and delivery systems, to later-stage licensing or commercialization agreements that align global go-to-market strategies. Manufacturers and service providers are investing in modular and flexible capacity to support heterogeneous product types-ranging from nucleic acid constructs requiring tight cold chain to cell-based products requiring individualized processing. In addition, some companies are integrating digital health and patient support solutions into launch plans to simplify administration logistics, monitor outcomes, and demonstrate real-world value.

Competitive differentiation also stems from regulatory acumen and payer engagement. Firms that proactively build robust health economic dossiers, engage with regulators on adaptive evidence pathways, and deploy early access programs are better positioned to secure favorable reimbursement arrangements and rapid uptake. Collectively, company strategies are converging on the need for end-to-end capabilities that link scientific innovation with scalable manufacturing, regulatory foresight, and commercially viable access models.

Practical and prioritized actions for developers and manufacturers to secure supply resilience, streamline regulatory engagement, and prove long-term value to payers and patients

Industry leaders should adopt a set of actionable priorities that balance scientific ambition with operational resilience and payer-oriented evidence generation. First, diversify supplier networks for critical inputs and prioritize qualification of alternate manufacturers to mitigate trade-related and single-source risks. Investing in regional manufacturing capacity or strategic partnerships can reduce exposure to cross-border policy changes while shortening lead times for clinical and commercial supply.

Second, integrate health economics and outcomes research into development programs from early phases to ensure that clinical trial design captures endpoints meaningful to regulators and payers alike. Employ adaptive trial designs and real-world evidence strategies to accelerate regulatory engagement and facilitate coverage discussions. Third, align platform selection with realistic manufacturing and distribution pathways. For instance, RNA-based approaches should be matched with cold chain optimization and delivery innovations, whereas viral vector programs require specialized containment and potency testing regimes.

Fourth, pursue targeted collaborations that combine antigen discovery capabilities, delivery expertise, and commercial channel access. These partnerships can accelerate translational timelines while sharing cost and risk. Fifth, engage proactively with regulators and payers through transparent evidence plans, early scientific advice sessions, and value demonstration pilots. Finally, augment commercial readiness with patient-centric access programs, digital adherence tools, and tailored distribution models that reflect the administration route and end-user capabilities. By operationalizing these priorities, industry leaders can convert scientific breakthroughs into durable clinical benefit and sustainable market access.

A transparent and multi-method research approach that integrates literature synthesis, expert interviews, pipeline analysis, and supply chain diagnostics for robust insights

The research methodology underpinning this analysis employed a rigorous, multi-source approach to ensure validity, reliability, and relevance for strategic decision-makers. The process began with a comprehensive review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, patent filings, and industry white papers to establish a baseline understanding of scientific advances and regulatory precedents. This secondary research informed targeted primary engagement, which included structured interviews with clinical investigators, manufacturing experts, regulatory advisors, payer representatives, and supply chain specialists to capture practitioner perspectives and operational constraints.

In parallel, a systematic mapping of technology platforms, manufacturing workflows, and administration routes was conducted to identify critical dependency points and scalability considerations. Clinical pipeline analysis focused on trial design heterogeneity, endpoint selection, and combination therapy strategies, while supply chain diagnostics assessed raw material sourcing, cold chain vulnerabilities, and contract manufacturing capacity. Analytic techniques included thematic synthesis of qualitative data, cross-validation of stakeholder claims against regulatory documents and trial registries, and scenario-based impact assessment to evaluate policy and tariff sensitivities.

Finally, findings were triangulated through iterative expert review and validation sessions to ensure interpretation robustness and practical applicability. This blended methodology balances depth of clinical and technical insight with pragmatic considerations of manufacturing, regulatory, and commercial viability, producing an evidence-informed foundation for the recommendations presented herein.

A conclusive synthesis emphasizing the need to align scientific innovation with manufacturing resilience, payer engagement, and segmented program planning for real-world impact

In conclusion, therapeutic vaccines occupy a pivotal role in the future of precision medicine, offering the prospect of durable disease control across oncology, infectious diseases, autoimmune conditions, and select neurological disorders. Scientific progress in nucleic acid platforms, viral vectors, and cell-based approaches, combined with evolving regulatory pathways and manufacturing innovations, has created a fertile environment for meaningful clinical advances. However, realizing that potential depends on proactive management of supply chain resilience, early alignment with payers and regulators, and careful orchestration of manufacturing and distribution strategies to support diverse administration routes and end-user settings.

Stakeholders who integrate segmented program planning-aligning indication-specific biology with platform capabilities, administration logistics, and distribution channels-will be well-positioned to navigate clinical complexity and access challenges. Moreover, the trade policy shifts witnessed in 2025 underscore the strategic value of supplier diversification and regional manufacturing planning. By coupling scientific rigor with operational foresight and payer-focused evidence generation, developers can translate immunologic innovation into sustainable therapeutic solutions that deliver measurable benefit to patients and health systems alike.

The strategic imperative is clear: to convert technological promise into real-world impact, organizations must synchronize R&D priorities with pragmatic manufacturing investments, adaptive regulatory engagement, and thoughtful market-access planning that ensures therapies reach the patients who need them.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Therapeutic Vaccines Market, by Indication

  • 8.1. Autoimmune Diseases
    • 8.1.1. Lupus
    • 8.1.2. Multiple Sclerosis
    • 8.1.3. Rheumatoid Arthritis
    • 8.1.4. Type 1 Diabetes
  • 8.2. Cancer
    • 8.2.1. Breast Cancer
    • 8.2.2. Cervical Cancer
    • 8.2.3. Colorectal Cancer
    • 8.2.4. Melanoma
    • 8.2.5. Prostate Cancer
  • 8.3. Infectious Diseases
    • 8.3.1. CMV
    • 8.3.2. Hepatitis
    • 8.3.3. HIV
    • 8.3.4. HPV
    • 8.3.5. Influenza
  • 8.4. Neurological Disorders
    • 8.4.1. Alzheimer's Disease
    • 8.4.2. Amyotrophic Lateral Sclerosis
    • 8.4.3. Epilepsy
    • 8.4.4. Parkinson's Disease

9. Therapeutic Vaccines Market, by Technology Platform

  • 9.1. Dendritic Cell
  • 9.2. Peptide
  • 9.3. RNA
    • 9.3.1. mRNA
    • 9.3.2. Self Amplifying RNA
  • 9.4. Viral Vector
    • 9.4.1. Adenovirus
    • 9.4.2. Lentivirus
    • 9.4.3. Vaccinia Virus
  • 9.5. Whole Cell

10. Therapeutic Vaccines Market, by Administration Route

  • 10.1. Intradermal
  • 10.2. Intramuscular
  • 10.3. Intravenous
  • 10.4. Subcutaneous

11. Therapeutic Vaccines Market, by End User

  • 11.1. Clinics
  • 11.2. Hospitals
  • 11.3. Research Institutes

12. Therapeutic Vaccines Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Therapeutic Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Therapeutic Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Therapeutic Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Therapeutic Vaccines Market

17. China Therapeutic Vaccines Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agenus Inc.
  • 18.6. AstraZeneca
  • 18.7. BioNTech SE (active in personalized cancer vaccines)
  • 18.8. Celldex Therapeutics
  • 18.9. CSL Limited
  • 18.10. CureVac
  • 18.11. Dendreon Pharmaceuticals LLC
  • 18.12. GSK plc
  • 18.13. Immatics Biotechnologies
  • 18.14. Inovio Pharmaceuticals
  • 18.15. Johnson & Johnson
  • 18.16. Merck & Co., Inc.
  • 18.17. Moderna
  • 18.18. Novartis AG
  • 18.19. Pfizer, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL THERAPEUTIC VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL THERAPEUTIC VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LUPUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LUPUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LUPUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CERVICAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CMV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CMV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CMV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HEPATITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HIV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HIV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HIV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HPV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HPV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HPV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DENDRITIC CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DENDRITIC CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DENDRITIC CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SELF AMPLIFYING RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SELF AMPLIFYING RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SELF AMPLIFYING RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINIA VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINIA VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINIA VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY WHOLE CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY WHOLE CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY WHOLE CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. GCC THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. GCC THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 251. GCC THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 252. GCC THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 253. GCC THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 254. GCC THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 255. GCC THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 256. GCC THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 257. GCC THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 258. GCC THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 259. GCC THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. GCC THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. G7 THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. G7 THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 287. G7 THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 288. G7 THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 289. G7 THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 290. G7 THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 291. G7 THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 292. G7 THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 293. G7 THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 294. G7 THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 295. G7 THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. G7 THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 297. NATO THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 298. NATO THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 299. NATO THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 300. NATO THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 301. NATO THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 302. NATO THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 303. NATO THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 304. NATO THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 305. NATO THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 306. NATO THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 307. NATO THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. NATO THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 309. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 322. CHINA THERAPEUTIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 324. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 325. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY CANCER, 2018-2032 (USD MILLION)
  • TABLE 326. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 327. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 328. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY TECHNOLOGY